Single Daily Dosing of Aminoglycosides: A Commentary

Gilbert DN . Once-daily aminoglycoside therapy. Amimicrob Agents Chemother 1991; 35: 399–405.

Zaske DE Cipolle RJ Rotschafer JC Solem LD Mosier NR Strate RG . Gentamicin pharmacokinetics in 1,640 patients: Method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21: 407–11.

Rotschafer JC Zabinski RA Walker KJ . Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992; I2: 64S–70S.

Bourget P Fernandez H Delouis C Taburet AM . Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen. J Clin Pharm Ther 1991; 16: 167–76.

Kafetzis DA Sianidou L Vlachos E Davros J Bairamis T Papandreou Y Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991; 27: 105–12.

International ATCG. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93.

Marik PE Havlik I Monteagudo FSE Lipman J . The pharmacokinetics of amikacin in critically ill adult and paediatric patients: Comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother 1991; 27: 81–9.

Marik PE Lipman J Kobilski S Scribante J . A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753–4.

Meunier F Van der Auwera P Aoun M Ibrahim S Tulkins PM . Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: A pilot study. J Antimicrob Chemother 1991; 27: 129–39.

Rozdzinski E Kern WV Reichie A Mortiz T Schmeiser T Gaus W Once-daily versus thrice-daily dosing of netilmicin in combination with—lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585–98.

Skopnik H Wallraf R Nies B Troster K Heimann G . Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992; 67: 57–61.

Vigano A Principi N Brivio L Tommasi P Stasi P Villa Dalla A . Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992; 36: 1499–503.

Nicolau DP Belliveau PP Freeman CD Nightingale CH Quintiliani R . Once-daily aminoglycosides (ODA): experience with 500 patients in a hospital-wide program (abstract 85). Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, October 1993.

DeBroe ME Verbist L Verpooten GA . Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27: 41–7.

Beaucaire G Leroy O Beuscart C Karp P Chidiac C Caillaux M Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991; 27: 91–103.

Konrad F Wagner R Neumeister B Rommel H Georgieff M . Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 1993; 19: 215–20.

Kapusnik JE Hackbarth CJ Chambers HF Carpenter T Sande MA . Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988; 158: 7–12.

Leoni F Ciolli S Pascarella A Fanci R Caporale R Ferrini PR . Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 1993; 39: 147–52.

Maller R Ahrne H Holmen C Lausen I Nilsson LE Smedjegard J Onceversus twice-daily amikacin regimen: Efficacy and safety in systemic gram-negative infections. J Antimicrob Chemother 1993; 31: 939–48.

Prins JM Buller HR Kuijper EJ Tange RA Speelman P . Once versus thrice-daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–8.

Peloquin CA Cumbo TJ Schentag JJ . Kinetics and dynamics of tobramycin action in patients with bacteriuria given single doses. Antimicrob Agents Chemother 1991; 35: 1191–5.

TerBraak EW DeVries PJ Bouter KP Van der Vegt SG Dorrestein GC Nortier JW Once-daily dosing regimen for aminoglycoside plus—lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58–66.

Valcke YJ Vogelaers DP Colardyn FA Pauwels RA . Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992; 101: 1028–32.

Vanhaeverbeek M Siska G Herchuelz A . Pharmacokinetics of oncedaily amikacin in elderly patients. J Antimicrob Chemother 1993; 31: 185–7.

Tulkens PM . Pharmacokinetic and toxicological evaluation of a oncedaily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991; 27: 49–61.

Tulkens PM . Efficacy and safety of aminoglycosides once-a-day: Experimental and clinical data. Scand J Infect Dis 1991; 74: 249–57.

Van der Auwera P Meunier F Ibrahim S Kaufman L Derde MP Tulkens PM . Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35: 640–7.

Van der Auwera P . Pharmacokinetic evaluation of single daily dose amikacin. J Antimicrob Chemother 1991; 27: 63–8.

Verpooten GA Giuliano RA Verbist L Eestermans G DeBroe ME . Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22–7.

Zhanel GG Ariano RE . Once daily aminoglycoside dosing: Maintained efficacy with reduced nephrotoxicity? Ren Fail 1992; 14: 1–9.

Moore RD Lietman PS Smith CR . Clinical response to aminoglycoside therapy: Importance of the ratio of the peak concentration to minimum inhibitory concentration. J Infect Dis 1987; 155: 93–8.

Levison ME Bush LM . Pharmacodynamics of antimicrobial agents: Bactericidal and postantibiotic effects. Infect Dis Clin North Am 1989; 3: 415–21.

Vogelman B Craig W . Kinetics of antimicrobial activity. J Pediatr 1986; 5: 835–40.

Blaser J . Efficacy of onceand thrice-daily dosing of aminoglycosides in in-vitro models of infection. J Antimicrob Chemother 1991; 27: 21–8.

Daikos GL Lolans VT Jackson GG . First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117–23.

Vogelman B Gudmundsson S Leggett J Ebert S Craig WA . Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 157: 287–98.

Wood CA Norton DR Kohlhepp SJ Kohnen PW Bennett WM Porter G The influence of tobramycin dosage regimen on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22.

Barclay ML Begg EJ Chambers ST . Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother 1992; 36: 1951–7.

Daikos GL Jackson GG Lolans VT Livermore DM . Adaptive resistance to aminoglycoside antibiotics from first-exposure down regulation. J Infect Dis 1990; 162: 414–20.

Jackson GG Lolans VT Daikos GL . The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162: 408–13.

Craig WA Gudmundsson S . The postantibiotic effect. In: Lorian V , ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1991: 515–36.

Remmeberg J Walder M . Postantibiotic effects of imipenem, norfloxacin, and amikacin in-vitro and in-vivo. Antimicrob Agents Chemother 1989; 33: 1714–20.

Fantin B Ebert S Leggett J Vogelman B Craig WA . Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram negative bacilli. J Antimicrob Chemother 1990; 27: 829–36.

McGrath BJ Lamp KC Rybak MJ . Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother 1993; 37: 1931–7.

Karlowsky JA Zhanel GG Davidson RJ Zieroth SR Hoban DJ . In vitro postantibiotic effects following multiple exposures of cefotaxime. ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth. Antimicrob Agents Chemother 1993; 37: 1154–7.

McGrath BJ Marchbanks R Gilbert D Dudley MN . In vitro postantibiotic effect following repeated exposure to imipenem, temafloxacin, and tobramycin. Antimicrob Agents Chemother 1993; 37: 1723–5.

Bodey GP Chang HY Rodriguez V Stewart D . Feasibility of administering aminoglycoside antibiotics by continuous infusion. Antimicrob Agents Chemother 1975; 8: 328–33.

Keating MJ Bodey GP Valdivieso M Rodriguez V . A randomized trial of three aminoglycosides. 1979; 58: 159–70.

Issell BF Keating MJ Valdivieso M Bodey GP . Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients. Am J Med Sei 1979; 277: 311–8.

Reiner NE Bloxham DD Thompson WL . Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978; 4 (suppl A):85–101.